"Did I do a good job? Do you think Biden could have done this? I don't think so," said President Donald Trump to the reporters assembled at the Oval Office after he made the announcement that he had secured a deal to slash the price of obesity drugs. His website, TrumpRx, will offer the sale of drugs like Wegovy and Zepbound, for only around $250 a month, which is a fraction of their current retail price which is more than $1,000. While it is a breakthrough, as many private insurances do not cover obesity drugs, and often forces people to pay for these injections out of pocket, experts point out that this system is not entirely flawless.Also Read: TrumpRx Lowered Prices Of Popular Weight Loss Drugs; What More Does Trump's New Medical Website Offer? TrumpRx Is Not FlawlessDrug policy experts say that while the administration has promised drugs at a cheaper rate, some of these discounts have not been approved yet by the Food and Drug Administration. The problem is that the lower prices for people paying out of pocket would only apply to the lowest doses of the drugs, however, the deal does not expand Medicare coverage to people seeking treatment for weight loss alone. Juliette Cubanski, who is the deputy director of Medicare policy program at KFF, said, and as is reported in NBC News, "It’s a situation where we have more questions than answers. Based on what we didn’t hear, that suggests to me that there’s a lot that the administration itself hasn’t even ironed out as of yet. It just feels a little bit too squishy right now."Art Caplan, also reported in NBC News, who is the head of the division of medical ethics at NYU Grossman School of Medicine in New York City, said, "It’s just murky as to how this will take shape, how the programs will work. You can’t really tell from what’s going on.”Are There Unapproved Drugs On The List?Several drugs and forms of drugs included in the deal are actually not approved by the FDA. These include oral versions of weight loss drugs, and Eli Lilly's new multidose injection pens. In fact, Lawrence Gostin, director of the O'Neill Institute for National and Global Health Law at Georgetown University said that the administration has made premature promises because the lower prices cannot take effect until the products are on the market. "It is reckless to negotiate pricing deals on products which the FDA have not yet approved as safe and effective. The administration is getting way out ahead of its own safety agency.”The list includes:Oral weight loss pills by WegovyOral weight loss pills by Novo NordiskMultidose version of ZepboundPrices Are Low, But People May End Up Paying MoreWhile the White House did say that both the pills and injection pens will be available for discounted prices for those who pay out of pocket, policy makers say that they may end up paying more. The starting doses of weight loss pill will cost $149 per month, and the shots will cost around $350 for a month's supply. The price of the injection is further expected to fall to about $259 within two years. However, when people start with the drugs, they start with the lowest dose that allows the body to get used to the drug, However, over the course of time, the dose increases to be effective for weight loss. For Wegovy, the highest doses are five, for Zepbound, it is six, and the most weight loss has seen with the highest doses.Officials said the starting dose of GLP-1 pills will cost $149 per month, though they didn’t clarify pricing for higher doses.For injections, the White House offered only a “weighted average” estimate of $350 a month. Lilly later specified that Zepbound will start at $299 for the lowest dose, rising to $449 for higher ones. Novo Nordisk didn’t confirm dose-based pricing and said it will share updated cost details in the coming weeks.All of this means patients using TrumpRx could ultimately pay significantly more than the administration’s headline prices, especially since most people don’t remain on the lowest dose for long, Caplan noted.
Email
Google
Facebook Email Google Facebook